

House
File
2042
-
Introduced


HOUSE
FILE
2042


BY
ISENHART


A
BILL
FOR


An
Act
relating
to
the
information
provided
a
patient
prior
1


to
prescribing
a
controlled
substance
for
acute
or
chronic
2


pain.
3


BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
4


TLSB
5641YH
(4)
88


pf/rh



H.F.
2042


Section
1.
NEW
SECTION
.
124.559
Provision
of
information
——
1


prescribing
of
controlled
substances
for
acute
or
chronic
pain.
2


1.
Prior
to
issuing
an
initial
prescription
for
a
schedule
3


II
controlled
substance
or
any
other
prescription
opioid
in
a
4


course
of
treatment
for
acute
or
chronic
pain,
and
again
prior
5


to
issuing
the
third
prescription
in
the
course
of
treatment,
6


a
prescribing
practitioner
shall
discuss
with
the
patient,
7


or
the
patient’s
parent
or
guardian
if
the
patient
is
under
8


eighteen
years
of
age
and
is
not
an
emancipated
minor,
the
9


risks
associated
with
the
substance
being
prescribed,
including
10


but
not
limited
to:
11


a.
The
risks
of
addiction
and
overdose
associated
with
12


opioid
drugs
and
the
dangers
of
taking
opioid
drugs
with
13


alcohol,
benzodiazepines,
and
other
central
nervous
system
14


depressants.
15


b.
The
reasons
why
the
prescription
is
necessary.
16


c.
Alternative
treatments
that
may
be
available.
17


d.
The
risks
associated
with
the
use
of
the
substance
18


being
prescribed,
specifically
that
opioids
are
highly
19


addictive,
even
when
taken
as
prescribed,
that
there
is
a
20


risk
of
developing
a
physical
or
psychological
dependence
on
21


the
substance
and
that
the
risks
of
taking
more
opioids
than
22


prescribed,
or
mixing
sedatives,
benzodiazepines
or
alcohol
23


with
opioids,
can
result
in
fatal
respiratory
depression.
24


2.
The
prescribing
practitioner
shall
include
a
note
25


in
the
patient’s
medical
record
that
the
patient
or
the
26


patient’s
parent
or
guardian,
as
applicable,
has
discussed
27


with
the
practitioner
the
risks
of
developing
a
physical
or
28


psychological
dependence
on
the
prescribed
substance
and
29


alternative
treatments
that
may
be
available.
30


3.
This
section
shall
not
apply
to
a
prescription
for
the
31


substances
specified
for
a
patient
who
is
currently
in
active
32


treatment
for
cancer
or
receiving
hospice
or
palliative
care
33


through
a
hospice
program
as
defined
in
section
135J.1,
for
the
34


resident
of
a
long-term
care
facility,
or
to
any
substances
35


-1-


LSB
5641YH
(4)
88


pf/rh


1/
3




H.F.
2042


that
are
being
prescribed
for
use
in
the
treatment
of
substance
1


use
disorder
or
opioid
dependence.
2


4.
As
used
in
this
section:
3


a.
“Long-term
care
facility”
means
the
same
as
defined
in
4


section
231.4.
5


b.
“Prescribing
practitioner”
means
the
same
as
defined
in
6


section
124.550.
7


Sec.
2.
CODE
EDITOR
DIRECTIVE.
The
Code
editor
shall
8


designate
section
124.559,
as
enacted
in
this
Act,
as
a
new
9


subchapter
within
chapter
124.
10


EXPLANATION
11


The
inclusion
of
this
explanation
does
not
constitute
agreement
with
12


the
explanation’s
substance
by
the
members
of
the
general
assembly.
13


This
bill
relates
to
the
information
to
be
provided
by
a
14


prescribing
practitioner
to
a
patient
prior
to
the
prescribing
15


of
a
controlled
substance
for
acute
or
chronic
pain.
The
bill
16


provides
that
prior
to
issuing
an
initial
prescription
of
a
17


schedule
II
controlled
substance
or
any
other
prescription
18


opioid
in
a
course
of
treatment
for
acute
or
chronic
pain,
and
19


again
prior
to
issuing
the
third
prescription
in
the
course
of
20


treatment,
a
prescribing
practitioner
shall
discuss
with
the
21


patient,
or
the
patient’s
parent
or
guardian
if
the
patient
22


is
under
18
years
of
age
and
is
not
an
emancipated
minor,
the
23


risks
associated
with
the
substance
being
prescribed.
The
24


information
to
be
discussed
includes
but
is
not
limited
to:
25


the
risks
of
addiction
and
overdose
associated
with
opioid
26


drugs
and
the
dangers
of
taking
opioid
drugs
with
alcohol,
27


benzodiazepines,
and
other
central
nervous
system
depressants;
28


the
reasons
why
the
prescription
is
necessary;
alternative
29


treatments
that
may
be
available;
and
the
risks
associated
with
30


the
use
of
the
substance
being
prescribed.
The
prescribing
31


practitioner
shall
include
a
note
in
the
patient’s
medical
32


record
that
the
patient
or
the
patient’s
parent
or
guardian,
33


as
applicable,
has
discussed
with
the
practitioner
the
risks
34


of
developing
a
physical
or
psychological
dependence
on
the
35


-2-


LSB
5641YH
(4)
88


pf/rh


2/
3



H.F.
2042


prescribed
substance
and
alternative
treatments
that
may
be
1


available.
The
bill
does
not
apply
to
a
prescription
for
2


the
substances
specified
in
the
bill
for
a
patient
who
is
3


currently
in
active
treatment
for
cancer
or
receiving
hospice
4


or
palliative
care
through
a
hospice
program,
for
the
resident
5


of
a
long-term
care
facility,
or
to
any
substances
that
are
6


being
prescribed
for
use
in
the
treatment
of
substance
use
7


disorder
or
opioid
dependence.
8


-3-


LSB
5641YH
(4)
88


pf/rh


3/
3

